SEGMENT INFORMATION - Reconciliation of net loss (Details) - USD ($) $ in Thousands |
3 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Operating expenses | ||||
| Research and development expense | $ (1,942) | $ (6,754) | $ (24,323) | $ (31,809) |
| Depreciation expense | (882) | (1,984) | (6,067) | (8,302) |
| Loss on impairment and lease termination | (17,063) | |||
| Loss from operations | (6,491) | (13,122) | (63,588) | (56,520) |
| Total other income (expense), net | (2,084) | 252 | (10,257) | 2,176 |
| Net income (loss) | (8,575) | (12,870) | (73,845) | (54,344) |
| Single reportable segment | ||||
| Operating expenses | ||||
| Reimbursement from JDAs and others | 3,410 | 34 | 1,686 | 3,570 |
| Payroll expense | (5,860) | (8,133) | (26,375) | (35,638) |
| Occupancy expense | (859) | (1,497) | (6,292) | (7,124) |
| Professional service expense | (916) | (606) | (4,146) | (3,671) |
| Research and development expense | (933) | (537) | (3,646) | (2,990) |
| Depreciation expense | (882) | (1,984) | (6,067) | (8,302) |
| Loss on impairment and lease termination | (17,063) | |||
| Other operating expense | (451) | (399) | (1,685) | (2,365) |
| Loss from operations | (6,491) | (13,122) | (63,588) | (56,520) |
| Total other income (expense), net | (10,257) | 2,176 | ||
| Net income (loss) | $ (8,575) | $ (12,870) | $ (73,845) | $ (54,344) |
| X | ||||||||||
- Definition Loss incurred due to termination of lease and impairment of assets. No definition available.
|
| X | ||||||||||
- Definition Amount of reimbursement from joint development agreement and other reimbursements. No definition available.
|
| X | ||||||||||
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of net occupancy expense that may include items, such as depreciation of facilities and equipment, lease expenses, property taxes and property and casualty insurance expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|